Literature DB >> 15455193

Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis.

Robert Lindsay1, Simon Pack, Zhengqing Li.   

Abstract

AIM: To determine the longitudinal progression of fractures through a population of osteoporotic women with no existing vertebral fractures.
METHODS: The probability of having one or more vertebral fractures in the next year given a current status of 0-13 existing vertebral fractures was estimated using data from control patients of an osteoporosis clinical trial program. Fracture probabilities were used to form a transition matrix that models the change in fracture state from one year to the next. A Markov model was used to show the distribution of fracture prevalence over time for a population of women with osteoporosis but, initially, with no existing vertebral fractures.
RESULTS: An osteoporotic woman without existing vertebral fractures has a 7.7% chance (95% CI, 5.8% to 9.9%) of having a vertebral fracture within 1 year. After 5 years, 33% (95% CI, 25% to 41%) will have developed vertebral fractures, of which 11% (95% CI, 8% to 16%) will have > or =2 fractures. After 10 years, 55% (95% CI, 44% to 65%) will have developed vertebral fractures, of which 29% (95% CI, 22% 37%) will have > or =2 fractures. Each 1% absolute reduction in the annual first-fracture risk corresponds to an approximate 4% reduction in the 5-year fracture incidence. Therefore, reducing the risk of first fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to approximately 10%.
CONCLUSIONS: Fracture prevalence rapidly increases over time in a population of osteoporotic women despite treatment with calcium and vitamin D supplements. Identifying and treating patients at risk of fracture, but who have not yet sustained a fracture, will substantially reduce the long-term burden of osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15455193     DOI: 10.1007/s00198-004-1691-5

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  26 in total

1.  Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density.

Authors:  C H Chesnut; N H Bell; G S Clark; B L Drinkwater; S C English; C C Johnson; M Notelovitz; C Rosen; D F Cain; K A Flessland; N J Mallinak
Journal:  Am J Med       Date:  1997-01       Impact factor: 4.965

Review 2.  Clinical consequences of vertebral fractures.

Authors:  P D Ross
Journal:  Am J Med       Date:  1997-08-18       Impact factor: 4.965

3.  Epidemiology of vertebral fractures in women.

Authors:  L J Melton; S H Kan; M A Frye; H W Wahner; W M O'Fallon; B L Riggs
Journal:  Am J Epidemiol       Date:  1989-05       Impact factor: 4.897

Review 4.  The clinical impact of vertebral fractures: quality of life in women with osteoporosis.

Authors:  D T Gold
Journal:  Bone       Date:  1996-03       Impact factor: 4.398

5.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

6.  Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group.

Authors:  D M Kado; W S Browner; L Palermo; M C Nevitt; H K Genant; S R Cummings
Journal:  Arch Intern Med       Date:  1999-06-14

7.  Pre-existing fractures and bone mass predict vertebral fracture incidence in women.

Authors:  P D Ross; J W Davis; R S Epstein; R D Wasnich
Journal:  Ann Intern Med       Date:  1991-06-01       Impact factor: 25.391

8.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

9.  Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study.

Authors:  R Hasserius; M K Karlsson; B E Nilsson; I Redlund-Johnell; O Johnell
Journal:  Osteoporos Int       Date:  2003-01       Impact factor: 4.507

10.  Risedronate reduces the risk of first vertebral fracture in osteoporotic women.

Authors:  R P Heaney; T M Zizic; I Fogelman; W P Olszynski; P Geusens; C Kasibhatla; N Alsayed; G Isaia; M W Davie; C H Chesnut
Journal:  Osteoporos Int       Date:  2002       Impact factor: 4.507

View more
  22 in total

Review 1.  Detection of vertebral fractures.

Authors:  Elliott N Schwartz; Dee Steinberg
Journal:  Curr Osteoporos Rep       Date:  2005-12       Impact factor: 5.096

2.  Short-term effects of extracorporeal shock wave therapy on bone mineral density in postmenopausal osteoporotic patients.

Authors:  L Shi; F Gao; W Sun; B Wang; W Guo; L Cheng; Z Li; W Wang
Journal:  Osteoporos Int       Date:  2017-07-06       Impact factor: 4.507

3.  Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency.

Authors:  Gherardo Mazziotti; Mauro Doga; Stefano Frara; Filippo Maffezzoni; Teresa Porcelli; Luigi Cerri; Roberto Maroldi; Andrea Giustina
Journal:  Endocrine       Date:  2015-10-03       Impact factor: 3.633

4.  Are bilateral decubitus views necessary in assessing for vertebral compression fractures using DXA vertebral fracture assessment?

Authors:  Y-C Lin; T-S Huang; J S Wu; Y-C Cheung; Y-H Huang; C-M Sung; Y-H Juan; F-P Chen; J M Ni Mhuircheartaigh
Journal:  Osteoporos Int       Date:  2017-05-09       Impact factor: 4.507

5.  Severity of vertebral fracture reflects deterioration of bone microarchitecture.

Authors:  H K Genant; P D Delmas; P Chen; Y Jiang; E F Eriksen; G P Dalsky; R Marcus; J San Martin
Journal:  Osteoporos Int       Date:  2006-10-07       Impact factor: 4.507

6.  Corrigendum to how to define an osteoporotic vertebral fracture.

Authors: 
Journal:  Quant Imaging Med Surg       Date:  2019-11

7.  Trends in fracture incidence: a population-based study over 20 years.

Authors:  Shreyasee Amin; Sara J Achenbach; Elizabeth J Atkinson; Sundeep Khosla; L Joseph Melton
Journal:  J Bone Miner Res       Date:  2014-03       Impact factor: 6.741

Review 8.  Is there a specific fracture 'cascade'?

Authors:  L Joseph Melton; Shreyasee Amin
Journal:  Bonekey Rep       Date:  2013-06-26

9.  Vertebral morphometry by dual-energy X-ray absorptiometry (DXA) for osteoporotic vertebral fractures assessment (VFA).

Authors:  D Diacinti; G Guglielmi; D Pisani; D Diacinti; R Argirò; C Serafini; E Romagnoli; S Minisola; C Catalano; V David
Journal:  Radiol Med       Date:  2012-06-28       Impact factor: 3.469

10.  The relationship of an Asian-specific screening tool for osteoporosis to vertebral deformity and osteoporosis.

Authors:  Sunee Saetung; Boonsong Ongphiphadhanakul; Rajata Rajatanavin
Journal:  J Bone Miner Metab       Date:  2008-01-10       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.